Connect with us

Biotechnology

Big Deals in Biotech Increase As Industry Looks to Capitalize on the Healthy Market

Joe Samuel

Published

on

biotechnology stock price

Junior biotech organizations have been obtaining more interest this year. Recently, Boehringer Ingelheim’s shopping spree continued with a EUR210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016.

The privately-held German drug maker was targeting the investment with ViraTherapeutics’ lead candidate VSV-GP, a cancer therapy that works by infecting tumors with a virus that both destroys malignant cells directly and mobilizes an immune response against them.

In addition, German biotech Affimed has previously agreed to deal with Roche’s Genentech to discover new cancer immunotherapies with an amazing $5 billion-dollar deal.

A few stocks to look at include: CEL-SCI Corporation (CVM), Roche Holdings, Inc. (RHHBY), Affirmed N.V. (AFMD), and Marinus Pharmaceuticals, Inc. (MRNS)

CEL-SCI Corporation

Market Cap: $105.57M, Share Price: $3.86

CEL-SCI Corporation announced that the company has received $5,435,367 through the exercise of warrants to purchase shares of the Company’s common stock during August through September 13, 2018. As of September 13, 2018, CEL-SCI had 27,351,324 outstanding shares of common stock.

Roche Holdings, AG.

Market Cap: $207B Share Price: $30.68

Mentioned above, Roche is the parent company to Genentech, which is host to the potential $5 billion dollar deal. The company is currently facing concerns in the UK regarding the pricing of its MS drug.

Affirmed N.V.

Market Cap: $265.15M Share Price: $4.25

Affirmed is the company Roche made the deal with and the stock has consolidated a bit since its large jump following the news.

Marinus Pharmaceuticals, Inc.

Market Cap: $283.67M Share Price: $7.00

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, CEO, Christopher M. Cashman, recently presented a company overview at the Baird 2018 Healthcare Conference.

Continue Reading
Click to comment

Biotechnology

Active Biotech Stocks To Watch As Markets Flirt With New Highs

A. Lawrence

Published

on

biotech stocks to watch

Biotech stocks is often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Investors need to watch the market closely and be aware of the latest news from the sector in order to make the best choices. Here is a look at 3 biotech stocks that turned heads in the biotech sector this week.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”

For more on PharmaCyte, Click Here

VIVUS (VVUS)

The first biotech stock to consider here is that of VIVUS, Inc. (NASDAQ:VVUS), which has rallied on Wednesday on the back of a major announcement from the company. The stock rallied by 3% this morning in premarket trade after the results were announced from the Phase 1 clinical trial of its product Qsymia. The medicine in question is a capsule and is meant for people who suffer from binge eating disorder.

It should be noted that medicine is currently approved in the United States when used by people in order to reduce calories in their diets. It is a major development for VIVUS and it is no surprise that the stock rallied today.

Diffusion Pharmaceuticals (DFFN)

The other biotech stock that is worth including in the watch list is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), which made solid gains yesterday on the back of the announcement of positive preliminary data from the Phase 3 clinical trial of Trans Sodium Crocetinate (TSC). The medicine is meant for treating inoperable glioblastoma and in the results, it has been revealed that patients recorded a median survival duration of as long as 14.3 months.

Historically, the standard survival duration is only 9.2 months. The results triggered a rally in the stock and the Diffusion stock soared by as much as 67.60%.

list of healthcare stocks to watch

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

Biotech Names To Know In November 2019

A. Lawrence

Published

on

best biotechnology stocks to buy sell

Biotech Stocks Have rallied since The End Of September; What’s Next?

Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.

In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,

Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”

Read This Full Press Release Here

Genprex (GNPX)

The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.

The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.

 Can Fite Biopharma (CANF)

The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.

The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.

top biotech stocks to watch list

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

The Biotech Index Just Hit New Highs; Stocks To Watch

Joe Samuel

Published

on

biotechnology stocks to watch

The Biotech ETF – IBB – Just Made New November Highs, What’s Next?

Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.

However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

What Happened This Week?

top biotech stocks to buy

This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner

NovaBay Pharmaceuticals (NBY)

The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.

The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.

REPORT: 1 Biotech Stock is Positioning Itself for Success

BioCryst Pharmaceuticals (BCRX)

Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.

In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.

REPORT: 1 Biotech Stock is Positioning Itself for Success

make money with penny stocks biotech

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com